454170-83-3

Upstream product

• 4407-36-7 (2E)-3-phenyl-2-propen-1-ol 
• 135733-30-1 3-(hydroxymethyl)-4-phenylfuroxan 
• 123-08-0 4-hydroxy-benzaldehyde 
• 104-54-1 3-Phenylpropenol 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 217966-10-4 3-chloromethyl-4-phenyl-1,2,5-oxadiazole N²-oxide 

Downstream Products

• 1235587-46-8 C₃₃H₂₄N₂O₉ 
• 1245644-41-0 O₅-acetyl-O₇-chrysinacetic acid [4-(4-phenyl-1,2,5-oxadiazole-2-oxide-3-yl)methoxyl]benzyl ester 
• 1257642-15-1 (E)-4-((4-phenyl-1,2,5-oxadiazol-3-yl)methoxy)benzyl 3-(4-(ethoxycarbonyloxy)-3-methoxyphenyl)acrylate 
• 1043914-17-5 3-[(4-({4-[(2-oxido-4-phenyl-1,2,5-oxadiazol-3-yl)methoxy]benzyl}oxy)-4-oxobutanoyl)oxy]olean-12-en-28-oic acid 
• 1043914-24-4 4-[(2-oxido-4-phenyl-1,2,5-oxadiazol-3-yl)methoxy]benzyl 3-[(trifluoroacetyl)oxy]olean-12-en-28-oate 
• 1043914-18-6 28-ethoxy-28-oxoolean-12-en-3-yl 4-[(2-oxido-4-phenyl-1,2,5-oxadiazol-3-yl)methoxy]benzyl succinate 

Relevant academic research and scientific papers

[...] derivative and its inflammation and immune dysfunction disease in the use of the

The present invention discloses uses of a class of brusatol derivatives and uses of the brusatol derivatives in inflammations and immune function disorder diseases, particularly to a class of nitric oxide donor brusatol derivatives or medically acceptable salts thereof, a pharmaceutical composition containing the derivative, and applications of the derivatives or the salts thereof in preparation of anti-inflammatory and immunosuppressive drugs. In addition, the applications of the derivatives are provided in preparation of drugs for inflammations and/or immune disorder related diseases. The formula I is defined in the instruction.

Design, synthesis and in vitro NO-releasing activities of ocotillol-type furoxans

A series of novel ocotillol-type furoxan derivatives was synthesized by coupling various furoxans to 3-OH of 6-deoxy ocotillol, and their in vitro nitric oxide (NO) releasing capability was studied. The discharge of NO was examined after 30 min at two dif

Furoxan nitric oxide donor coupled chrysin derivatives: Synthesis and vasculoprotection

A series of furoxan-based nitric oxide-releasing chrysin derivatives were synthesized. Pharmacological assays indicated that all chrysin derivatives exhibited in vitro inhibitory activities against aldose reductase and advanced glycation end-product formation. Some chrysin derivatives were also found to increase the glucose consumption of HepG2 cells. Furthermore, the compounds released a low amount of NO in the presence of l-cysteine (range from 0.20% to 1.89%). These hybrid furoxan-based NO donor chrysin derivatives offer a mutual prodrug design concept for the development of therapeutic or preventive agents for vascular complications due to diabetes.